Some batches of Durisan hand sanitizer have been previously recalled and in a new update, the company has further expanded the recall. The U.S. Food and Drug Administration (FDA) explained that the move was due to the fact that the affected hand sanitizers were contaminated with a type of bacteria that could infect the users.
The expanded recall announcement
Based on the FDA’s recall notice that was posted on Tuesday, May 18, Durisan Sanit Technologies updated the recall for its anti-microbial hand sanitizer products. Now, the batches of products to be recalled were expanded to add those that were manufactured after April 10, 2019, and have not expired yet.
The company made the decision because the affected bottles were said to have been contaminated with common bacteria called Burkholderia contaminans. People infected may not experience reactions but for others, they may suffer from more serious effects once the bacteria enter their bloodstream through scrapes or wounds after using the hand sanitizer.
An infection could result from this, as per the FDA. The agency also warned that people with weaker immune systems are more susceptible to infection so the use of the contaminated hand sanitizer is risky.
Other information of the recalled lots
Fox Business mentioned that as per the Centers for Disease Control and Prevention (CDC), Burkholderia cepacia is found in water and soil. This bacteria may also be a little complicated to treat because it is said to be usually resistant to common antibiotics.
In any case, the recalled Durisan hand sanitizer includes 47 lots of the products. These covered the ones packed in various bottle sizes of 18 ml credit cards, 118 ml, 236 ml, 300 ml and 500 ml. The wall-mounted dispensers that use 1000 ml bottles are also included.
Fortunately, there is no report of adverse reactions yet or complaints from customers regarding the contaminated Durisan hand sanitizer. With the voluntary recall of its maker, the FDA said that distributors and retailers were already notified too.
“Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to using this drug product,” the FDA wrote in the expanded recall announcement. “Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.”


SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Silver Prices Plunge in Asian Trade as Dollar Strength Triggers Fresh Precious Metals Sell-Off
Fed Governor Lisa Cook Warns Inflation Risks Remain as Rates Stay Steady
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Oil Prices Slide on US-Iran Talks, Dollar Strength and Profit-Taking Pressure
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
U.S. Stock Futures Edge Higher as Tech Rout Deepens on AI Concerns and Earnings
India Services Sector Rebounds in January as New Business Gains Momentum: HSBC PMI Shows Growth
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Gold and Silver Prices Rebound After Volatile Week Triggered by Fed Nomination
Asian Currencies Trade Sideways as Dollar Stabilizes, Yen Weakens Ahead of Japan Election
Trump Endorses Japan’s Sanae Takaichi Ahead of Crucial Election Amid Market and China Tensions
U.S.-India Trade Framework Signals Major Shift in Tariffs, Energy, and Supply Chains
Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns
Japan Economy Poised for Q4 2025 Growth as Investment and Consumption Hold Firm 



